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Background
The anti-diabetic drug metformin has been shown to
affect cancer cell metabolism [1,2] and to display anti-
tumoral properties in numerous cancers [3,4], however, its
role in the formation of metastases remains poorly docu-
mented. Cell migration is a critical step in the progression
of prostate cancer to the metastatic state, the lethal form
of the disease.
Results
We show here that metformin reduces the occurrence of
metastases in an orthotopic metastatic prostate cancer cell
model established in nude mice. As predicted, metformin
hampers cell motility in PC3 and DU145 prostate cancer
cells and triggers a radical reorganization of the cell cytos-
keleton. The small GTPase Rac1 is a master regulator of
cytoskeleton organization and cell migration. We report
that metformin inhibits Rac1 GTPase activity by interfer-
ing with some of its multiple upstream signaling pathways,
namely P-Rex1 (a Guanine nucleotide exchange factor and
activator of Rac1), cyclic AMP and CXCL12/CXCR4,
resulting in decreased migration of prostate cancer cells.
Importantly, overexpression of a constitutively active form
of Rac1 (Rac1-Q61L or Rac1-V12), or P-Rex1 as well as
the inhibition of the adenylate cyclase were able to reverse
the anti-migratory effects of metformin.
Conclusion
Our results establish a novel mechanism of action for
metformin through Rac1 and highlight its potential anti-
metastatic properties in prostate cancer.
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